THR-149 is one of a pair of drugs Oxurion has in mid-stage testing for DE along with pan-RGD integrin antagonist THR-687, which is in the phase 2 INTEGRAL study in previously-untreated DME patients.

We then isolated cell surface receptors for RGD. These were some of the founding members of the integrin family of receptors. RGD-like compounds are now used in the clinic as antithrombotics and ...

As targeted therapies are receiving more attention in the laboratory and clinic, several key focus areas deserve attention. The search for agents that prevent tumor invasion is one of the major ...

Anti-integrin αvβ6 antibody (Ab) is present in sera of UC patients in a highly specific manner. We investigated if there were any associations between anti-integrin αvβ6 Ab and TAK, considering the ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.